Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE IN EUROPE
Watch the discussion between Philippe H Kolh, Silvia Giuliana Priori and Dirk Van Veldhuisen.
Get all the latest ESC Pocket Guidelines, plus interactive tools (algorithms, calculators, charts, scores...) in your pocket.
what's new in the 2015 ESC Guidelines?
1. Preamble 2. Introduction 2.1 Structure of the guidelines 3. Definitions, epidemiology and future perspectives for theprevention of sudden cardiac death 3.1 Epidemiology of sudden cardiac death 3.2 Indications for autopsy and molecular autopsy in sudden death victims 3.3 Risk prediction of sudden cardiac death 3.4 Prevention of sudden cardiac death in special settings 4. Therapies for ventricular arrhythmias 4.1 Treatment of underlying heart disease4.2 Pharmacotherapy for ventricular arrhythmia and prevention of sudden cardiac death 4.3 Device therapy 4.4 Cardioversion or defibrillation and acute treatment of sustained ventricular arrhythmias 4.5 Interventional therapy 4.6 Psychosocial impact of implantable cardioverter defibrillator treatment 5. Management of ventricular arrhythmias and prevention of sudden cardiac death in coronary artery disease 5.1 Acute coronary syndromes 5.2 Early after myocardial infarction 5.3 Stable coronary artery disease after myocardial infarction with preserved ejection fraction 6. Therapies for patients with left ventricular dysfunction, with or without heart failure 6.1 Primary prevention of sudden cardiac death 6.2 Premature ventricular complexes in patients with structural heart disease/left ventricular dysfunction 6.3 Sustained ventricular tachycardia7. Cardiomyopathies7.1 Dilated cardiomyopathy 7.2 Hypertrophic cardiomyopathy 7.3 Arrhythmogenic right ventricular cardiomyopathy 7.4 Infiltrative cardiomyopathies 7.5 Restrictive cardiomyopathy 7.6 Other cardiomyopathies8. Inherited primary arrhythmia syndromes 8.1 Long QT syndrome8.2 Short QT syndrome 8.3 Brugada syndrome8.4 Catecholaminergic polymorphic ventricular tachycardia 8.5 Early repolarization syndrome 9. Paediatric arrhythmias and congenital heart disease 9.1 Management of ventricular arrhythmias in children with a structurally normal heart9.2 Sudden cardiac death and ventricular arrhythmias in patients with congenital heart disease 9.3 Implantable cardioverter defibrillator therapy in paediatric patients 10. Ventricular tachycardias and ventricular fibrillation in structurally normal hearts 10.1 Outflow tract ventricular tachycardias10.2 Ventricular tachycardias of miscellaneous origin 10.3 Idiopathic ventricular fibrillation 10.4 Short-coupled torsade de pointes 11. Inflammatory, rheumatic and valvular heart diseases 11.1 Myocarditis 11.2 Endocarditis 11.3 Rheumatic heart disease .11.4 Pericarditis 11.5 Cardiac sarcoidosis 11.6 Valvular heart disease 12. Arrhythmic risk in selected populations 12.1 Psychiatric patients 12.1.1 Epidemiology 12.1.2 Diagnosis 12.1.3 Treatment 12.2 Neurological patients 12.3 Pregnant patients12.4 Obstructive sleep apnoea 12.5 Drug-related pro-arrhythmia 12.6 Sudden cardiac death after heart transplantation 12.7 Sudden cardiac death in athletes 12.8 Wolff–Parkinson–White syndrome 12.9 Prevention of sudden cardiac death in the elderly 12.10 End-of-life issues13. Gaps in evidence14. To do and not to do messages from the guidelines